Journal
CANCER LETTERS
Volume 380, Issue 2, Pages 525-533Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2014.09.035
Keywords
Ang-2 targeting; Angiogenesis; Anti-angiogenic therapy; VEGF targeting; Combination therapy
Categories
Funding
- NCI (US Public Health Service Grants) [R01 CA089655, R01 CA084408]
- NIH T32 training grant [5T32 CA009126-33]
Ask authors/readers for more resources
Anti-angiogenic therapies target the tumor vasculature, impairing its development and growth. It was hypothesized over 40 years ago by the late Judah Folkman and Julie Denekamp that depriving a tumor of oxygen and nutrients, by targeting the tumor vasculature, could have therapeutic benefits. Identification of growth factors and signaling pathways important in angiogenesis subsequently led to the development of a series of anti-angiogenic agents that over the past decade have become part of the standard of care in several disease settings. Unfortunately not all patients respond to the currently available anti-angiogenic therapies while others become resistant to these agents following prolonged exposure. Identification of new pathways that may drive angiogenesis led to the development of second generation anti-angiogenic agents such as those targeting the Ang-2/Tie2 axis. Recently, it has become clear that combination of first and second generation agents targeting the blood vessel network can lead to outcomes superior to those using either agent alone. The present review focuses on the current status of VEGF and Ang-2 targeted agents and the potential utility of using them in combination to impair tumor angiogenesis. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available